CMO/CSO/EVP Adv Tech/Product @irhythmtech. Professor and founding director @stanfordcdh. Cardiac EP, scientist, trialist, AI builder. Views mine.
San Francisco, CA
Based in United States
- Tweets 6,019
- Following 1,439
- Followers 6,483
- Likes 6,520
Mintu Turakhia, MD MS retweeted
In 1980, 21% of NIH-funded principal investigators were under age 35. By 2015, this proportion was 3%.
The dramatic ageing of independent scientists is bad because old people are simply worse at science than young people.
Latest meta-scientific deep-dive from me 🧵 ⬇️
52
141
1,061
329,269
The editorial is drawing artificial distinctions of what AI can and cannot do, and it seems aspirational in what it purports that all clinicians do today. Even if they do increase accountability, some of the human characteristics listed could arguably increase bias, too.
3
316
A terrific choice to lead @nyulangone through its next chapter. @SVRaoMD is unique — peerless in many ways — and will do great things and bring the program to new heights.
We’re pleased to announce that @SVRaoMD has been named director of the Leon H. Charney Division of Cardiology, where he’ll oversee clinical care, research, and education while advancing innovation in cardiovascular medicine.
Learn more about Dr. Rao: bit.ly/3SAav1t
15
1,343
I would revise “beyond cardioversion…” to “for six months and maybe getting a cardioversion along the way.” That’s all the trial answered.
6
304
That doesn’t matter. The trial should not be interpreted that patient in AF should unconditionally stay in AF. The paper’s conclusion is well written. I’m more worried about the spin.
1
2
112
Hard disagree. LLMs outperform the median clinician. Not everyone can be above the median, despite everyone thinking they are.
Is there proof that LLMs don’t access the full copy of papers?
There are over 2000 pages of cardiovascular guidelines alone generated each year. Humans can’t keep up.
1
2
10
808
Agree. I need to dig in to the paper. But I would have liked to see longitudinal measurement of QOL, starting weeks post ablation and extending to at least a year.
The other issue is if QOL was measuring a placebo affect or contraventions, like other forms of rhythm control, in the sham group.
1
5
140
Even if the primary endpoint was met, all-cause mortality is the only outcome that matters and is what other primary prevention ICD trials have used.
3
275
There is a risk of credentialism then. There are really good operators who have at least a few years of clinical experience of working in different systems, leading large teams, executing against resource constraints, and growing revenue while maintaining clinical excellence.
1
5
655
Why do you think that they are selecting folks straight out of training rather than seasoned clinicians longer health system experience or physician operators?
2
4
3,839
Not a great question. Verapamil-sensitive VT (or Belhassen's VT) is a clinical entity referring to a re-entrant fascicular VT with part of the circuit that is sensitive to calcium channel blockade. While verapamil isn't the right choice in poly VT, there are instances where it is the right drug.
Which of the following drugs should NOT be used in the management of ventricular tachycardia ?
A) Amiodarone
B) Lidocaine
C) Verapamil
D) Procainamide
1
2
5
2,228
Congrats to @gregorymmarcus and his team. Greg is unique in cardiovascular science: time after time, Greg does the studies that are hard but sound, challenge dogma, and others aren’t able or willing to do.
Contrary to our hypothesis, we found in a randomized crossover trial of smoked/ vaped #cannabis, that exposure to the drug led to LESS cardiac ectopy (mainly driven by less premature atrial contractions, an important predictor of #afib); no differences in sleep, step counts or glucose using wearable sensors. @DrDave01 @leftbundle @drjohnm @PrashSanders @ethanjweiss @NguyenHEARTYlab @UCSFCardiology @UCSF @DebbeMcCall @stopafib @KnowYourPulse Congrats to first author @Adielias5
Full text link: authors.elsevier.com/a/1nbTn…
19
5,140
These are rational choices in academic medicine when RVUs pay the way. The real disparity is that clinician scientists can only do science if they can afford to — independent wealth, high spousal income, or self sacrifice. The system must change.
I've dropped 90% of my academic work, will be giving my last lectures at major international conferences soon, resigned from editorial committees, have stopped reviewing papers, and will never be the lead author on another paper. Same salary, same benefits, more free time.
3
3
39
10,603